StockNews.com upgraded shares of HUTCHMED (NASDAQ:HCM – Free Report) from a hold rating to a buy rating in a report issued on Wednesday morning.
Separately, Cantor Fitzgerald reiterated an overweight rating on shares of HUTCHMED in a research note on Friday, January 12th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of Moderate Buy and a consensus target price of $29.70.
Get Our Latest Stock Analysis on HUTCHMED
HUTCHMED Stock Up 1.2 %
Institutional Investors Weigh In On HUTCHMED
Institutional investors and hedge funds have recently bought and sold shares of the business. Quantbot Technologies LP bought a new stake in shares of HUTCHMED during the first quarter valued at approximately $44,000. China Universal Asset Management Co. Ltd. increased its holdings in HUTCHMED by 353.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,593 shares of the company’s stock valued at $65,000 after acquiring an additional 2,801 shares during the last quarter. US Bancorp DE lifted its stake in HUTCHMED by 270.9% in the 1st quarter. US Bancorp DE now owns 3,687 shares of the company’s stock worth $70,000 after purchasing an additional 2,693 shares in the last quarter. Tower Research Capital LLC TRC boosted its holdings in shares of HUTCHMED by 28.8% during the 3rd quarter. Tower Research Capital LLC TRC now owns 5,723 shares of the company’s stock valued at $97,000 after purchasing an additional 1,279 shares during the last quarter. Finally, National Pension Service boosted its holdings in shares of HUTCHMED by 429.1% during the 2nd quarter. National Pension Service now owns 9,101 shares of the company’s stock valued at $115,000 after purchasing an additional 7,381 shares during the last quarter. 8.82% of the stock is owned by institutional investors.
About HUTCHMED
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors.
Featured Stories
- Five stocks we like better than HUTCHMED
- What is Forex and How Does it Work?
- Best Bear Market Funds: Top 3 Investment Options to Consider
- What is an Earnings Surprise?
- Is DraftKings A Good Bet Ahead of Q1 Earnings?
- How to Choose Top Rated Stocks
- Mid-Cap Stocks to Outperform the Market This Cycle
Receive News & Ratings for HUTCHMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHMED and related companies with MarketBeat.com's FREE daily email newsletter.